Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address unmet needs for patients with generalized myasthenia gravis.

and nipocalimab for myasthenia gravis. Merck & Co.’s clesrovimab is an investigational prophylactic long-acting monoclonal antibody (mAb) targeted at the RSV fusion glycoprotein that is designed ...

Higher Quantitative Myasthenia Gravis-Revised (QMG ... "Additional FcRn inhibitors, such as nipocalimab and batoclimab, have produced promising results in clinical trials and may soon achieve ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations and those who did not experience exacerbations. A new report offers ...

that are integral to the pathogenesis of generalized myasthenia gravis," noted Richard Nowak, MD, MS, of Yale University in New Haven, Connecticut. In the Vivacity-MG3 trial, nipocalimab lessened ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

such as generalized myasthenia gravis. Dr. Narayanaswami, who contributed to the research, expressed optimism about nipocalimab's unique properties in addressing these conditions' underlying causes.